Use of Iontophoresis Technology for Transdermal Delivery of a Minimal mRNA Vaccine as a Potential Melanoma Therapeutic.
iontophoresis
melanoma
minimal mRNA vaccine
Journal
Biological & pharmaceutical bulletin
ISSN: 1347-5215
Titre abrégé: Biol Pharm Bull
Pays: Japan
ID NLM: 9311984
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
1
2
2023
pubmed:
2
2
2023
medline:
4
2
2023
Statut:
ppublish
Résumé
mRNA vaccines have attracted considerable attention as a result of the 2019 coronavirus pandemic; however, challenges remain regarding use of mRNA vaccines, including insufficient delivery owing to the high molecular weights and high negative charges associated with mRNA. These characteristics of mRNA vaccines impair intracellular uptake and subsequent protein translation. In the current study, we prepared a minimal mRNA vaccine encoding a tumor associated antigen human gp100
Identifiants
pubmed: 36724958
doi: 10.1248/bpb.b22-00746
doi:
Substances chimiques
Cancer Vaccines
0
mRNA Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM